VITRAKVI DIN 02490323
Status: Marketed
Holder: BAYER INC
Available to quote
Health Canada record
| Active ingredient(s) | LAROTRECTINIB (LAROTRECTINIB SULFATE) 100 MG |
|---|
| Dosage form | Capsule |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01EX12 LAROTRECTINIB |
|---|
| Original market date | 13-Nov-2020 |
|---|
| Current status date | 13-Nov-2020 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Bayer Inc — licence 101029, currently licensed, last inspection rating C (2023-02-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LAROTRECTINIB (LAROTRECTINIB SULFATE)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02490315 | VITRAKVI | BAYER INC | Capsule | LAROTRECTINIB (LAROTRECTINIB SULFATE) 25 MG | Marketed |
| 02490331 | VITRAKVI | BAYER INC | Solution | LAROTRECTINIB (LAROTRECTINIB SULFATE) 20 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 22387 | 2019-07-10 | New Drug Submission (NDS) | |
Request a quote for VITRAKVI
How to read a Canadian DIN record